Feng Wen

1.2k total citations
53 papers, 699 citations indexed

About

Feng Wen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Feng Wen has authored 53 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 22 papers in Surgery. Recurrent topics in Feng Wen's work include Gastric Cancer Management and Outcomes (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (9 papers). Feng Wen is often cited by papers focused on Gastric Cancer Management and Outcomes (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (9 papers). Feng Wen collaborates with scholars based in China, United States and Japan. Feng Wen's co-authors include Pengfei Zhang, Qiu Li, Hanrui Zheng, Wei‐Ting Liao, Kexun Zhou, Patrick M. Gaffney, Hongyuan Liang, Zaiming Lu, Yu Yang and Qiyong Guo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Feng Wen

49 papers receiving 688 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feng Wen China 14 252 218 206 139 131 53 699
Sandra J. Casak United States 18 114 0.5× 455 2.1× 215 1.0× 109 0.8× 171 1.3× 32 1.0k
M. Puglisi Italy 16 115 0.5× 539 2.5× 408 2.0× 111 0.8× 257 2.0× 38 998
Scot Dowden Canada 14 124 0.5× 624 2.9× 285 1.4× 119 0.9× 81 0.6× 24 826
Jason B. Litten United States 9 102 0.4× 132 0.6× 87 0.4× 47 0.3× 202 1.5× 21 537
Liming Wang China 15 292 1.2× 197 0.9× 121 0.6× 132 0.9× 148 1.1× 62 663
Vincenzo Dadduzio Italy 18 297 1.2× 451 2.1× 258 1.3× 99 0.7× 164 1.3× 39 834
Marcus Smith Noel United States 13 73 0.3× 521 2.4× 135 0.7× 70 0.5× 160 1.2× 68 803
Kian Fong Foo Singapore 13 129 0.5× 320 1.5× 238 1.2× 64 0.5× 141 1.1× 24 712
Kristen Spencer United States 14 76 0.3× 506 2.3× 286 1.4× 165 1.2× 205 1.6× 59 924
S. Palmeri Italy 17 91 0.4× 584 2.7× 228 1.1× 48 0.3× 121 0.9× 78 821

Countries citing papers authored by Feng Wen

Since Specialization
Citations

This map shows the geographic impact of Feng Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Wen more than expected).

Fields of papers citing papers by Feng Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Wen. The network helps show where Feng Wen may publish in the future.

Co-authorship network of co-authors of Feng Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Feng Wen. A scholar is included among the top collaborators of Feng Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng Wen. Feng Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Junqi, Chenlu Yang, Feng Wen, et al.. (2025). Targeting mitochondrial complex I of CD177+ neutrophils alleviates lung ischemia-reperfusion injury. Cell Reports Medicine. 6(5). 102140–102140. 2 indexed citations
2.
3.
4.
Zheng, Hanrui, Jiafeng Li, Feng Wen, & Na Su. (2023). Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma. Frontiers in Oncology. 13. 1216960–1216960. 1 indexed citations
5.
Wen, Feng, et al.. (2023). Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis. Clinical and Experimental Medicine. 23(7). 3981–3994. 1 indexed citations
6.
7.
Liao, Wei‐Ting, David W. Hutton, Qiuji Wu, et al.. (2021). Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Frontiers in Oncology. 11. 692005–692005. 1 indexed citations
8.
Yang, Yang, Liangliang Bai, Wei‐Ting Liao, et al.. (2021). Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer. Journal of Translational Medicine. 19(1). 391–391. 44 indexed citations
9.
Liao, Wei‐Ting, Jiaxing Huang, Qiuji Wu, et al.. (2019). Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis. Oral Oncology. 93. 15–20. 8 indexed citations
10.
Wen, Feng, et al.. (2019). Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis. World Journal of Clinical Cases. 7(20). 3247–3258. 22 indexed citations
11.
Liu, Xin, et al.. (2019). Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load. The Brazilian Journal of Infectious Diseases. 23(5). 343–351. 10 indexed citations
12.
13.
Wen, Feng, Hanrui Zheng, Pengfei Zhang, David W. Hutton, & Qiu Li. (2018). OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open. 8(4). e020128–e020128. 9 indexed citations
14.
Zhang, Pengfei, Feng Wen, & Qiu Li. (2016). FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and Liver Disease. 48(12). 1492–1497. 22 indexed citations
15.
Zhou, Jing, Feng Wen, Pengfei Zhang, et al.. (2016). Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of Cancer Research and Clinical Oncology. 143(2). 361–368. 25 indexed citations
16.
Wen, Feng, Hanrui Zheng, Yifan Wu, et al.. (2016). Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Scientific Reports. 6(1). 36060–36060. 4 indexed citations
17.
Zhang, Pengfei, Yu Yang, Feng Wen, et al.. (2015). Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology. 27(7). 853–859. 40 indexed citations
18.
Wen, Feng, et al.. (2013). Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anti-Cancer Drugs. 24(7). 754–758. 15 indexed citations
19.
Zhang, Xiaolong, Wei Wen, Wenxiu Yao, et al.. (2011). Clinical management of gastric cancer: results of a multicentre survey. BMC Cancer. 11(1). 369–369. 3 indexed citations
20.
Huang, Shizhou, et al.. (2002). The multifocal electroretinogram in central serous chorioretinopathy. Ophthalmic and Physiological Optics. 22(3). 244–247. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra J. Casak Breakdown of academic impact, for papers by M. Puglisi Breakdown of academic impact, for papers by Scot Dowden Breakdown of academic impact, for papers by Jason B. Litten Breakdown of academic impact, for papers by Liming Wang Breakdown of academic impact, for papers by Vincenzo Dadduzio Breakdown of academic impact, for papers by Marcus Smith Noel Breakdown of academic impact, for papers by Kian Fong Foo Breakdown of academic impact, for papers by Kristen Spencer Breakdown of academic impact, for papers by S. Palmeri
Rankless by CCL
2026